# A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

> **NCT04204616** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Galderma R&D** · enrollment: 500 (estimated)

## Conditions studied

- Prurigo Nodularis

## Interventions

- **DRUG:** Nemolizumab

## Key facts

- **NCT ID:** NCT04204616
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-11
- **Primary completion:** 2026-10-26
- **Final completion:** 2026-10-26
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2025-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04204616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04204616, "A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04204616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*